Vericel Q1 revenue up 30% to $68.4M, net loss narrows; raises FY revenue guidance to $326-336M

Vericel Corp

2026-Q1 EPS reported -$0.12 revenue$68,425,000

Total revenue up 30% to $68.4M; MACI revenue up 22% to $56.4M, Burn Care up 91% to $12.0M.
Net loss narrowed to $6.3M from $11.2M; adjusted EBITDA up 195% to $9.6M (14% of revenue).
Raised full-year 2026 revenue guidance by $10M to $326-336M; reaffirmed ~75% gross margin and ~27% adjusted EBITDA margin.
Free cash flow of $15.1M; cash and investments $211M, no debt.
Received FDA approval for MACI commercial manufacturing at new facility; BARDA award up to $197M for NexoBrid.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.